Specific egg yolk immunoglobulin as a new preventive approach for shiga-toxin-mediated diseases

PLoS ONE

Volumn 6, Issue 10, 2011, Pages

  Neri, Paola ^a   Tokoro, Shunji ^a   Kobayashi, Ryo ^a   Sugiyama, Tsuyoshi ^a   Umeda, Kouji ^b,f   Shimizu, Takeshi ^c   Tsuji, Takao ^d   Kodama, Yoshikatsu ^b,f   Oguma, Keiji ^e   Mori, Hiroshi ^a  

^a GIFU PHARMACEUTICAL UNIVERSITY   (Japan)

^b GHEN Corporation   (Japan)

^c CHIBA UNIVERSITY   (Japan)

^d FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e OKAYAMA UNIVERSITY   (Japan)

^f Immunology Research Institute   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; IMMUNOGLOBULIN ANTIBODY; IMMUNOGLOBULIN Y; MITOMYCIN C; SHIGA TOXIN; SHIGA TOXIN 1 IMMUNOGLOBULIN Y ANTIBODY; SHIGA TOXIN 2 IMMUNOGLOBULIN Y ANTIBODY; UNCLASSIFIED DRUG; VEROTOXIN 1; VEROTOXIN 2; EGG PROTEIN; IMMUNOGLOBULIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY DETECTION; ANTIBODY SPECIFICITY; ARTICLE; BACTERIAL INFECTION; CHICKEN; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; DRUG FECES LEVEL; ENTEROHEMORRHAGIC ESCHERICHIA COLI; ENZYME LINKED IMMUNOSORBENT ASSAY; ESCHERICHIA COLI O157; FEMALE; IN VIVO STUDY; INFECTION PREVENTION; INTESTINE INFECTION; MORTALITY; MOUSE; NONHUMAN; SHIGA TOXIN PRODUCING ESCHERICHIA COLI; TARGET CELL DESTRUCTION; WESTERN BLOTTING; ANIMAL; CROSS REACTION; ESCHERICHIA COLI INFECTION; FECES; HUMAN; IMMUNIZATION; IMMUNOLOGY; MALE; METHODOLOGY; ORAL DRUG ADMINISTRATION; PATHOGENICITY; SERODIAGNOSIS; SPECIES DIFFERENCE;

ESCHERICHIA COLI; GALLUS GALLUS; MUS;

ADMINISTRATION, ORAL; ANIMALS; ANTIBODY SPECIFICITY; CHICKENS; CROSS REACTIONS; EGG PROTEINS; ENTEROHEMORRHAGIC ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; FECES; FEMALE; HUMANS; IMMUNIZATION; IMMUNOGLOBULINS; MALE; MICE; NEUTRALIZATION TESTS; SHIGA TOXIN 1; SHIGA TOXIN 2; SPECIES SPECIFICITY;

EID: 80054791684     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0026526     Document Type: Article

References (61)

1. Karmali MA, Petric M, Lim C, Fleming PC, Arbus GS, et al. (1985) The association between idiopathic hemolytic uremic syndrome and infection by verotoxin-producing Escherichia coli. J Infect Dis 151: 775-782.
2. Paton JC, Paton AW, (1998) Pathogenesis and diagnosis of Shiga toxin-producing Escherichia coli infections. Clin Microbiol Rev 11: 450-479.
3. Kiyokawa N, Taguchi T, Mori T, Uchida H, Sato N, et al. (1998) Induction of apoptosis in normal human renal tubular epithelial cells by Escherichia coli Shiga toxins 1 and 2. J Infect Dis 178: 178-184.
4. Ergonul Z, Hughes AK, Kohan DE, (2003) Induction of apoptosis of human brain microvascular endothelial cells by Shiga toxin 1. J Infect Dis 187: 154-158.
5. Lingwood CA, Law H, Richardson S, Petric M, Brunton JL, et al. (1987) Glycolipid binding of purified and recombinant Escherichia coli produced verotoxin in vitro. J Biol Chem 262: 8834-8839.
6. Lindberg AA, Brown JE, Stromberg N, Westling-Ryd M, Schultz JE, et al. (1987) Identification of the carbohydrate receptor for Shiga toxin produced by Shigella dysenteriae type 1. J Biol Chem 262: 1779-1785.
7. Endo Y, Tsurugi K, Yutsudo T, Takeda Y, Ogasawara T, et al. (1988) Site of action of a Vero toxin (VT2) from Escherichia coli O157:H7 and of Shiga toxin on eukaryotic ribosomes. RNA N-glycosidase activity of the toxins. Eur J Biochem 171: 45-50.
8. Saxena SK, O'Brien AD, Ackerman EJ, (1989) Shiga toxin, Shiga-like toxin II variant, and ricin are all single-site RNA N-glycosidases of 28S RNA when microinjected into Xenopus oocytes. J Biol Chem 264: 596-601.
9. Wong CS, Jelacic S, Habeeb RL, Watkins SL, Tarr PI, (2000) The risk of the hemolytic-uremic syndrome after antibiotics treatment of Escherichia coli O157:H7 infections. N Engl J Med 342: 1930-1936.
10. Zhang X, McDaniel AD, Wolf LE, Keusch GT, Waldor MK, et al. (2000) Quinolone antibiotics induce Shiga toxin-encoding bacteriophages, toxin production, and death in mice. J Infect Dis 181: 664-670.
11. Yoh M, Honda T, (1997) The stimulating effect of fosfomycin, an antibiotic in common use in Japan, on the production/release of verotoxin-1 from enterohaemorrhagic Escherichia coli O157:H7 in vitro. Epidemiol Infect 119: 101-103.
12. Kitov PI, Sadowska JM, Mulvey G, Armstrong GD, Ling H, et al. (2000) Shiga-like toxins are neutralized by tailored multivalent carbohydrate ligands. Nature 403: 669-672.
13. Dohi H, Nishida Y, Furuta Y, Uzawa H, Yokoyama S, et al. (2002) Molecular design and biological potential of galacto-type trehalose as a nonnatural ligand of Shiga toxins. Org Lett 4: 355-357.
14. Mulvey GL, Marcato P, Kitov PI, Sadowska J, Bundle DR, et al. (2003) Assessment in mice of the therapeutic potential of tailored, multivalent Shiga toxin carbohydrate ligands. J Infect Dis 187: 640-649.
15. Watanabe M, Matsuoka K, Kita E, Igai K, Higashi N, et al. (2004) Oral therapeutic agents with highly clustered globotriose for treatment of Shiga toxigenic Escherichia coli infections. J Infect Dis 189: 360-368.
16. Nishikawa K, Matsuoka K, Watanabe M, Igai K, Hino K, et al. (2005) Identification of the optimal structure required for a Shiga toxin neutralizer with oriented carbohydrates to function in the circulation. J Infect Dis 191: 2097-2105.
17. Neri P, Nagano IS, Yokoyama S, Dohi H, Kobayashi K, et al. (2007) Neutralizing activity of polyvalent Gb3, Gb2 and galacto-trehalose models against Shiga toxins. Microbiol Immunol 51: 581-592.
18. Neri P, Tokoro S, Yokoyama S, Miura T, Murata T, et al. (2007) Monovalent Gb3-/Gb2-derivatives conjugated with a phosphatidyl residue: a novel class of Shiga toxin-neutralizing agent. Biol Pharm Bull 30: 1697-1701.
19. Ostroff SM, Kobayashi JM, Lewis JH, (1989) Infections with Escherichia coli O157:H7 in Washington State. The first year of statewide disease surveillance. JAMA 262: 355-359.
20. Boerlin P, McEwen SA, Boerlin-Petzold F, Wilson JB, Johnson RP, et al. (1999) Associations between virulence factors of Shiga toxin-producing Escherichia coli and disease in humans. J Clin Microbiol 37: 497-503.
21. Tesh VL, Burris JA, Owens JW, Gordon VM, Wadolkowski EA, et al. (1993) Comparison of the relative toxicities of Shiga-like toxins type I and type II for mice. Infect Immun 61: 3392-3402.
22. Nakajima H, Kiyokawa N, Katagiri YU, Taguchi T, Suzuki T, et al. (2001) Kinetic analysis of binding between Shiga toxin and receptor glycolipid Gb3Cer by surface plasmon resonance. J Biol Chem 276: 42915-42922.
23. Uzawa H, Ito H, Neri P, Mori H, Nishida Y, (2007) Glycochips from polyanionic glycopolymers as tools for detecting Shiga toxins. Chembiochem 8: 2117-2124.
24. Yamagami S, Motoki M, Kimura T, Izumi H, Takeda T, et al. (2001) Efficacy of postinfection treatment with anti-Shiga toxin (Stx) 2 humanized monoclonal antibody TMA-15 in mice lethally challenged with Stx-producing Escherichia coli. J Infect Dis 184: 738-742.
25. Mukherjee J, Chios K, Fishwild D, Hudson D, O'Donnell S, et al. (2002) Production and characterization of protective human antibodies against Shiga toxin 1. Infect Immun 70: 5896-5899.
26. Sheoran AS, Chapman-Bonofiglio S, Harvey BR, Mukherjee J, Georgiou G, et al. (2005) Human antibody against Shiga toxin 2 administered to piglets after the onset of diarrhea due to Escherichia coli O157:H7 prevents fatal systemic complications. Infect Immun 73: 4607-4613.
27. Krautz-Peterson G, Chapman-Bonofiglio S, Boisvert K, Feng H, Herman IM, et al. (2008) Intracellular neutralization of Shiga toxin 2 by an A subunit-specific human monoclonal antibody. Infect Immun 76: 1931-1939.
28. Reilly RM, Domingo R, Sandhu J, (1997) Oral delivery of antibodies. Future pharmacokinetic trends. Clin Pharmacokinet 32: 313-323.
29. Mine Y, Kovacs-Nolan J, (2002) Chicken egg yolk antibodies as therapeutics in enteric infectious disease: a review. J Med Food 5: 159-169.
30. Yokoyama H, Umeda K, Peralta RC, Hashi T, Icatlo FC Jr, et al. (1998) Oral passive immunization against experimental salmonellosis in mice using chicken egg yolk antibodies specific for Salmonella enteritidis and S. typhimurium. Vaccine 16: 388-393.
31. Shin JH, Yang M, Nam SW, Kim JT, Myung NH, et al. (2002) Use of egg yolk-derived immunoglobulin as an alternative to antibiotic treatment for control of Helicobacter pylori infection. Clin Diagn Lab Immunol 9: 1061-1066.
32. Amaral JA, Tino De Franco M, Carneiro-Sampaio MM, Carbonare SB, (2002) Anti-enteropathogenic Escherichia coli immunoglobulin Y isolated from eggs laid by immunised Leghorn chickens. Res Vet Sci 72: 229-234.
33. Cook SR, Bach SJ, Stevenson SML, DeVinney R, Frohlich AA, et al. (2005) Orally administered anti-Escherichia coli O157:H7 chicken egg yolk antibodies reduce fecal shedding of the pathogen by ruminants. Can J Anim Sci 85: 291-299.
34. Girard F, Batisson I, Martinez G, Breton C, Harel J, et al. (2006) Use of virulence factor-specific egg yolk-derived immunoglobulins as a promising alternative to antibiotics for prevention of attaching and effacing Escherichia coli infections. FEMS Immunol Med Microbiol 46: 340-350.
35. Strockbine NA, Marques LR, Newland JW, Smith HW, Holmes RK, et al. (1986) Two toxin-converting phages from Escherichia coli O157:H7 strain 933 encode antigenically distinct toxins with similar biologic activities. Infect Immun 53: 135-140.
36. Downes FP, Barrett TJ, Green JH, Aloisio CH, Spika JS, et al. (1988) Affinity purification and characterization of Shiga-like toxin II and production of toxin-specific monoclonal antibodies. Infect Immun 56: 1926-1933.
37. Jackson MP, Neill RJ, O'Brien AD, Holmes RK, Newland JW, (1987) Nucleotide sequence analysis and comparison of the structural genes for Shiga-like toxin I and Shiga-like toxin II encoded by bacteriophages from Escherichia coli 933. FEMS Microbiol Lett 44: 109-114.
38. Gentry KM, Dalrymple MJ, (1980) Quantitative microtiter cytotoxicity assay for Shigella toxin. J Clin Microbiol 12: 361-366.
39. O'Brien AD, Tesh VL, Donohue-Rolfe A, Jackson MP, Olsnes S, et al. (1992) Shiga toxin: biochemistry, genetics, mode of action, and role in pathogenesis. Curr Top Microbiol Immunol 180: 65-94.
40. Shimizu T, Kawakami S, Sato T, Sasaki T, Higashide M, et al. (2007) Serine 31 residue of B subunit of Shiga toxin 2 is essential for the secretion in Enterohemorrhagic Escherichia coli. Infect Immun 75: 2189-2200.
41. O'Brien AD, Laveck GD, (1983) Purification and characterization of Shigella dysenteriae 1-like toxin produced by Escherichia coli. Infect Immun 40: 675-683.
42. Lindgren SW, Samuel JE, Schmitt CK, O'Brien AD, (1994) The specific activities of shiga-like toxin type II (SLT-II) and SLT-II-related toxins of enterohemorrhagic Escherichia coli differ when measured by vero cell cytotoxicity but not by mouse lethality. Infect Immun 62: 623-631.
43. Yutsudo T, Nakabayashi N, Hirayama T, Takeda Y, (1987) Purification and some properties of a Vero toxin from Escherichia coli O157:H7 that is immunologically unrelated to Shiga toxin. Microb Pathog 3: 21-30.
44. Wen SX, Teel LD, Judge NA, O'Brien AD, (2006) Genetic toxoids of Shiga toxin types 1 and 2 protect mice against homologous but not heterologous toxin challenge. Vaccine 24: 1142-1148.
45. Head SC, Petric M, Richardson S, Roscoe M, Karmali MA, (1988) Purification and characterization of verocytotoxin 2. FEMS Microbiol Lett 51: 211-216.
46. Smith MJ, Teel LD, Carvalho HM, Melton-Celsa AR, O'Brien AD, (2006) Development of a hybrid Shiga holotoxoid vaccine to elicit heterologous protection against Shiga toxins types 1 and 2. Vaccine 24: 4122-4129.
47. Wang Q, Hou XJ, Cai K, Li T, Liu YN, et al. (2010) Passive protection of purified yolk immunoglobulin administered against Shiga toxin 1 in mouse models. Can J Microbiol 56: 1003-1010.
48. Tesh VL, Burris JA, Owens JW, Gordon VM, Wadolkowski EA, et al. (1993) Comparison of relative toxicities of Shiga-like toxins type I and type II for mice. Infect Immun 61: 3392-3402.
49. Flagler MJ, Strasser JE, Chalk CL, Weiss AA, (2007) Comparative analysis of the abilities of Shiga toxins 1 and 2 to bind to and influence neutrophil apoptosis. Infect Immun 75: 760-765.
50. Jeong KJ, Tzipori S, Sheoran AS, (2010) Stx2- but not Stx1-specific human monoclonal antibody protects piglets challenged with enterohemorrhagic Escherichia coli producing Stx1 and Stx2. J Infect Dis 201: 1081-1083.
51. Shimizu K, Asahara T, Nomoto K, Tanaka R, Hamabata T, et al. (2003) Development of a lethal Shiga toxin-producing Escherichia coli-infection mousemodel using multiple mitomycin C treatment. Microb Pathog 35: 1-9.
52. Acheson DWK, Moore R, De Breucker S, Lincicome L, Jacewicz M, et al. (1996) Translocation of Shiga toxin across polarized intestinal cells in tissue culture. Infect Immun 64: 3294-3300.
53. Hurley BP, Jacewicz M, Thorpe CM, Lincicome LL, King AJ, et al. (1999) Shiga toxin 1 and 2 translocate differently across polarized intestinal epithelial cells. Infect Immun 67: 6670-6677.
54. Zumbrun SD, Hanson L, Sinclair JF, Freedy J, Melton-Celsa AR, et al. (2010) Human intestinal tissue and cultured colonic cells contain globotriaosylceramide synthase mRNA and the alternate Shiga toxin receptor globotetraosylceramide. Infect Immun 78: 4488-4499.
55. Ostroff SM, Tarr PI, Neill MA, Lewis JH, Hargrett-Bean N, et al. (1989) Toxin genotypes and plasmid profiles as determinants of systemic sequelae in Escherichia coli O157:H7 infections. J Infect Dis 160: 994-998.
56. Nagano K, Taguchi K, Hara T, Yokoyama S, Kawada K, et al. (2003) Adhesion and colonization of enterohemorrhagic Escherichia coli O157:H7 in cecum of mice. Microbiol Immunol 47: 125-132.
57. Yokoyama S, Suzuki T, Shiraishi S, Ohishi N, Yagi K, et al. (2001) Construction of deletion mutants of Shiga (-like) toxin genes (stx-1 or/and stx-2) on enterohemorrhagic Escherichia coli (O157:H7). J Clin Biochem Nutr 30: 33-44.
58. Shimizu T, Sato T, Kawakami S, Ohta T, Noda M, et al. (2007) Receptor affinity, stability and binding mode of Shiga toxins are determinants of toxicity. Microb Pathog 43: 88-95.
59. Nakajima H, Katagiri YU, Kiyokawa N, Taguchi T, Suzuki T, et al. (2001) Single-step method for purification of Shiga toxin-1 B subunit using receptor-mediated affinity chromatography by globotriaosylceramide-conjugated octyl sepharose CL-4B. Protein Expr Purif 22: 267-275.
60. Tsuji T, Shimizu T, Sasaki K, Shimizu Y, Tsukamoto K, et al. (2008) Protection of mice from Shiga toxin-2 toxemia by mucosal vaccine of Shiga toxin 2B-His with Escherichia coli enterotoxin. Vaccine 26: 469-476.
61. Nagano K, Sugisaki T, Taguchi K, Hara T, Naiki M, et al. (2003) A murine model of enterohemorrhagic Escherichia coli O157:H7 infection to assess immunopotentiating activity of drugs on mucosal immunity: effect of drugs. J Pharmacol Sci 91: 219-228.